Literature DB >> 6496610

Acyclovir in the treatment of herpetic stromal disease.

J J Sanitato, P A Asbell, E D Varnell, G E Kissling, H E Kaufman.   

Abstract

Seventeen patients (ten women and seven men, 23 to 72 years old) with stromal herpetic disease were treated with topical and oral acyclovir for 14 days. Of the 12 patients with disciform edema, five showed minimal improvement, four showed no change, and three showed worsening of their disease. Of the five patients with necrotizing stromal keratitis, one improved, one showed no change, and three became worse. The patients who had been treated with corticosteroids previously had a statistically significantly worse outcome than those who had not been so treated. One patient with necrotizing stromal keratitis showed virus particles in tissue specimens obtained by superficial lamellar keratectomy. Thus, acyclovir was not effective in the treatment of disciform edema or necrotizing stromal keratitis. Further studies are needed to ascertain whether the drug is therapeutically ineffective or whether acyclovir did not reach the stroma in amounts sufficient to affect the course of stromal disease in the human eye.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6496610     DOI: 10.1016/0002-9394(84)90237-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  The enigma of herpes stromal disease.

Authors:  J McGill
Journal:  Br J Ophthalmol       Date:  1987-02       Impact factor: 4.638

2.  Recurrence rate of herpetic uveitis in patients on long-term oral acyclovir.

Authors:  A Rodriguez; W J Power; R A Neves; C S Foster
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

3.  In vitro synergism of trifluorothymidine and ganciclovir against HSV-1.

Authors:  Jeffery A Hobden; Manish Kumar; Herbert E Kaufman; Christian Clement; Emily D Varnell; Partha S Bhattacharjee; James M Hill
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-11       Impact factor: 4.799

4.  Mechanism of corneal permeation of L-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea.

Authors:  Banmeet S Anand; Ashim K Mitra
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

5.  A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva.

Authors:  Manish Kumar; James M Hill; Christian Clement; Emily D Varnell; Hilary W Thompson; Herbert E Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-15       Impact factor: 4.799

Review 6.  Rational acyclovir therapy in herpetic eye disease.

Authors:  M G Falcon
Journal:  Br J Ophthalmol       Date:  1987-02       Impact factor: 4.638

Review 7.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

8.  6-Thioguanine Inhibits Herpes Simplex Virus 1 Infection of Eyes.

Authors:  Deyan Chen; Ye Liu; Fang Zhang; Qiao You; Wenyuan Ma; Jing Wu; Zhiwei Wu
Journal:  Microbiol Spectr       Date:  2021-11-03

9.  Targeting herpetic keratitis by gene therapy.

Authors:  Hossein Mostafa Elbadawy; Marine Gailledrat; Carole Desseaux; Diego Ponzin; Stefano Ferrari
Journal:  J Ophthalmol       Date:  2012-12-26       Impact factor: 1.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.